Dr. Weidanz has over 20 years of experience in biotechnology research with emphasis in immunology, immunotherapy and immunodiagnostic product development, especially as these disciplines relate to oncology and the development of products to diagnose and treat cancer. His work has been funded from the NIH, DOD and American Heart Association. He is the founder and Chief Scientific Officer of Receptor Logic, Inc., and most recently served as its President. His other duties include serving as: 1) Chairman for the Department of Immunotherapeutics and Biotechnology, 2) Director for the Center for Immunotherapeutic Research and Product Development, and 3) a tenured Professor at Texas Tech University Health Sciences Center (TTUHSC). He received the President's Excellence in Teaching Award as well as the Chancellor's Council Distinguished Teaching Award for his innovative classroom instruction TTUHSC.
Dr. Weidanz has published studies involving therapeutic monoclonal antibodies, vaccine potency assays, dendritic cells and T cells related to vaccine development and assessment of immune modulators.In particular, Dr. Weidan zis intersted in a class of antibodies his group has named as T cell receptor mimickig (TCRm) antibodies. These antibodies bind to peptide/MHC complexes and ae useful as research tools to study antigen processing and presentation